Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Mar 2023
Today's top stories include: Nine-year cap to complete MBBS, elective-based credits offered in NMC letter Students enrolled in...
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.
Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.
IgA Nephropathy in 2025: Year in Review
1.
Study confirms link between breast density, higher breast cancer risk
2.
Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma
3.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
4.
A specific drug combination is being tested in a clinical trial for the deadly brain cancer glioblastoma.
5.
Advances in TNBC; Mixed News in Lung Cancer Report; Pancreatic Cancer Overdiagnosis?
1.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
2.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
3.
The Importance of Balanced Potassium Levels in Maintaining Good Health
4.
Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields
5.
Surgery for Tracheoesophageal Fistula: What to Expect Before, During, and After
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part I
2.
Updates on the First Line Management of ALK+ NSCLC
3.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge